Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Brief Report
Case Report
Editorial
Focus
Images/Instrument in Dermatology/Dermatosurgery
Innovations
Letter to the Editor
Living Legends
Looking back in history
Original Article
Perspective
Resident Forum
Review Article
Spot the Diagnosis
Tropical Dermatology
Visual Treats in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Brief Report
Case Report
Editorial
Focus
Images/Instrument in Dermatology/Dermatosurgery
Innovations
Letter to the Editor
Living Legends
Looking back in history
Original Article
Perspective
Resident Forum
Review Article
Spot the Diagnosis
Tropical Dermatology
Visual Treats in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Brief Report
Case Report
Editorial
Focus
Images/Instrument in Dermatology/Dermatosurgery
Innovations
Letter to the Editor
Living Legends
Looking back in history
Original Article
Perspective
Resident Forum
Review Article
Spot the Diagnosis
Tropical Dermatology
Visual Treats in Dermatology
View/Download PDF

Translate this page into:

Innovations
2023
:3;
89
doi:
10.25259/CSDM_105_2023

Xylometazoline in the treatment of post-acne macular erythema

Department of Dermatology, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, Maharashtra, India

*Corresponding author: Rachita S. Dhurat, Department of Dermatology, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, Maharashtra, India. rachitadhurat@yahoo.co.in

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Maanasa M, Dhurat RS, Sharma R, Ghate SS. Xylometazoline in the treatment of post-acne macular erythema. CosmoDerma 2023;3:89.

PROBLEM

Post-acne macular erythema refers to the localized areas of persistent skin erythema that occurs as acne lesions resolve.[1] This is more commonly seen following inflammatory acne and in lighter Fitzpatrick skin types. It is a common worrisome complication and can have significant psychological impact.

The pathogenesis is initially due to vasodilation but the persistent erythema seen in many cases is due to the cascade of inflammatory events that follow acne vulgaris and neovascularization.[2] It is considered a sign of ongoing inflammation and is important to initiate treatment early due to the chances of it resulting in scarring.[3] The existing therapeutic options include topicals such as tacrolimus, brimonidine, niacinamide, Vitamin C, and tranexamic acid and procedural treatments such as microneedling, intense pulse light, and lasers. However, all these may be associated with certain drawbacks ranging from partial response to cost to availability. Hence, arose the need for a versatile, inexpensive, and easily available molecule with good efficacy. We selected topical xylometazoline drops for the same.

SOLUTION

Xylometazoline is an imidazoline derivative. It is easily available as over the counter nasal drops and sprays. It is an alpha adrenergic receptor agonist resulting in vasoconstriction. It is routinely used as a nasal decongestant and for the control of epistaxis. Ten patients of significant post-acne macular erythema were treated with topical xylometazoline. Two drops were applied over each cheek followed by gentle massaging twice daily. Topical 1% clindamycin phosphate gel was given in case the patient developed breakthrough acne. Assessment was done by taking clinical photographs using Nikon digital camera D5300 at baseline and every 15 days thereafter. Patients showed complete resolution of erythema as early as 2 months up to 4 months after starting xylometazoline [Figures 1 and 2]. Follow-up at 5th months after stopping xylometazoline did not show signs of relapse. None of the patients have reported any side effects till date. Hence, xylometazoline is a safe, inexpensive, easily available, easy to apply, and efficacious treatment option for post-acne macular erythema. Absence of a control group is a limitation of our study.

(a) Baseline photo of patient 1, (b) Post 1.5 months photo of patient 1, (c) Post 3 months photo of patient 1.
Figure 1:
(a) Baseline photo of patient 1, (b) Post 1.5 months photo of patient 1, (c) Post 3 months photo of patient 1.
(a) Baseline photo of patient 2, (b) Post 15 days photo of patient 2.
Figure 2:
(a) Baseline photo of patient 2, (b) Post 15 days photo of patient 2.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Conflicts of interest

There are no conflicts of interest.

Financial support and sponsorship

Nil.

References

  1. , , , , , , et al. Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the personalising acne: Consensus of experts panel. JAAD Int. 2021;5:41-8.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Acne scars: Pathogenesis, classification and treatment. Dermatol Res Pract. 2010;2010:893080.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Prospective study of pathogenesis of atrophic acne 42 scars and role of macular erythema. J Drugs Dermatol. 2017;16:566-72.
    [Google Scholar]

Fulltext Views
1,526

PDF downloads
360
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections